A leading expert voices highly cautious optimism over the very few steps taken today that could help tackle the threat to ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Flightpath Biosciences, Inc., a clinical stage biotechnology company focused on the development of precision therapeutics targeting bacterial ...

Chinese biotech Brii Biosciences (HKEX: 2137) has licensed its experimental antibiotic BRII-693 to domestic pharma business ...

Only one antibiotic – Sulbactam-durlobactam (brand name: Xacduro) – was effective against CRAB. Approved by US regulators in ...

Scientists have used Artificial Intelligence to generate a ready-to-use biological protein that can kill antibiotic resistant ...

Anaerobic bacteria were among the first life forms on Earth and existed at a time when there was no oxygen in the atmosphere.

Feature Published: December 1999 The new antibiotics Holger Breithaupt Nature Biotechnology 17, 1165–1169 (1999) Cite this article ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma ...

Family offices made 60 direct investments in companies, ending three straight months of declining deal activity.